Navigating Treatment Sequencing in HER2+ Metastatic Breast Cancer: Evidence-Based Approaches - Episode 8
Tucatinib Combinations in HER2+ Breast Cancer: HER2CLIMB-02 and HER2CLIMB-05
Panelists discuss how the HER2CLIMB-02 and HER2CLIMB-05 trials might impact treatment sequencing, with particular interest in using tucatinib earlier in treatment to potentially prevent brain metastases.
Clinical Brief: Novel Clinical Trial Data in HER2-Positive (HER2+) Metastatic Breast Cancer
Key Themes:
- HER2CLIMB-02 Results: Addition of tucatinib to T-DM1 showed modest progression-free survival (PFS) improvement (9.5 vs 7.4 months) without overall survival benefit
- Subgroup Benefit: More pronounced benefit observed in patients with brain metastases (PFS, 7.8 vs 5.7 months)
- HER2CLIMB-05 Trial: Investigating tucatinib added to maintenance trastuzumab/pertuzumab following first-line THP
Key Points for Physicians:
- HER2CLIMB-02 results support the concept of dual HER2-directed therapy but may not substantially change practice
- The more notable benefit in patients with brain metastases reinforces tucatinib’s value in this population
- HER2CLIMB-05 data may provide insight into whether earlier tucatinib exposure could prevent development of brain metastases
Notable Insights:
- Not all positive trial results immediately change clinical practice, particularly when the benefit is modest
- The field is moving toward bringing effective agents into earlier lines of therapy
- The potential to prevent brain metastases through earlier use of agents with central nervous system (CNS) activity represents an important research direction
Clinical Significance:
Although HER2CLIMB-02 data showed modest benefit overall, the study results reinforce tucatinib’s value in patients with brain metastases and highlight the ongoing evolution of treatment sequencing in HER2+ metastatic breast cancer, with increasing interest in preventive strategies for CNS disease.
Related Content:
